BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pea A, Riva G, Bernasconi R, Sereni E, Lawlor RT, Scarpa A, Luchini C. Ampulla of Vater carcinoma: Molecular landscape and clinical implications. World J Gastrointest Oncol 2018; 10(11): 370-380 [PMID: 30487949 DOI: 10.4251/wjgo.v10.i11.370] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Palmeri M, Funel N, Franco GD, Furbetta N, Gianardi D, Guadagni S, Bianchini M, Pollina LE, Ricci C, Chiaro MD, Candio GD, Morelli L. Tissue microarray-chip featuring computerized immunophenotypical characterization more accurately subtypes ampullary adenocarcinoma than routine histology. World J Gastroenterol 2020;26:6822-36. [PMID: 33268964 DOI: 10.3748/wjg.v26.i43.6822] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Vanoli A, Grillo F, Furlan D, Arpa G, Grami O, Guerini C, Riboni R, Mastracci L, Di Sabatino A. Small Bowel Epithelial Precursor Lesions: A Focus on Molecular Alterations. Int J Mol Sci 2021;22:4388. [PMID: 33922305 DOI: 10.3390/ijms22094388] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Manne A, Hatic H, Li P, Jacob R, Williams G, Paluri R. The Clinical Benefit of Adjuvant Therapy in Long-Term Survival of Early-Stage Ampullary Carcinoma: A Single Institutional Experience. J Clin Med Res 2020;12:560-7. [PMID: 32849944 DOI: 10.14740/jocmr4267] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Pham NA, Radulovich N, Ibrahimov E, Martins-Filho SN, Li Q, Pintilie M, Weiss J, Raghavan V, Cabanero M, Denroche RE, Wilson JM, Metran-Nascente C, Borgida A, Hutchinson S, Dodd A, Begora M, Chadwick D, Serra S, Knox JJ, Gallinger S, Hedley DW, Muthuswamy L, Tsao MS. Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers. Sci Rep 2021;11:10619. [PMID: 34011980 DOI: 10.1038/s41598-021-90049-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Mettman D, Saeed A, Shold J, Laury R, Ly A, Khan I, Golem S, Olyaee M, O'Neil M. Refined pancreatobiliary UroVysion criteria and an approach for further optimization. Cancer Med 2021. [PMID: 34374212 DOI: 10.1002/cam4.4043] [Reference Citation Analysis]
6 Vicentini C, Calore F, Nigita G, Fadda P, Simbolo M, Sperandio N, Luchini C, Lawlor RT, Croce CM, Corbo V, Fassan M, Scarpa A. Exosomal miRNA signatures of pancreatic lesions. BMC Gastroenterol 2020;20:137. [PMID: 32375666 DOI: 10.1186/s12876-020-01287-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
7 Hayata Y, Nakagawa H, Kurosaki S, Kawamura S, Matsushita Y, Hayakawa Y, Suzuki N, Hata M, Tsuboi M, Kinoshita H, Miyabayashi K, Mizutani H, Nakagomi R, Ikenoue T, Hirata Y, Arita J, Hasegawa K, Tateishi K, Koike K. Axin2+ Peribiliary Glands in the Periampullary Region Generate Biliary Epithelial Stem Cells That Give Rise to Ampullary Carcinoma. Gastroenterology 2021;160:2133-2148.e6. [PMID: 33465373 DOI: 10.1053/j.gastro.2021.01.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ali J, Khan A, Ahmed MH, Madhotra R. Secondary Tumors of the Ampulla of Vater: A Tale of Two Cases. J Lab Physicians 2021;13:384-7. [PMID: 34975261 DOI: 10.1055/s-0041-1732810] [Reference Citation Analysis]
9 Pothuri V, Herndon J, Ballentine SJ, Lim KH, Fields RC. A Case of a Pathological Complete Response to Neoadjuvant Nivolumab plus Ipilimumab in Periampullary Adenocarcinoma. Oncologist 2021;26:722-6. [PMID: 33982365 DOI: 10.1002/onco.13821] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 de Jong EJM, Mommers I, Fariña Sarasqueta A, van der Geest LG, Heij L, de Hingh IHJT, Homs MYV, Tjan-Heijnen VCG, Valkenburg-van Iersel LBJ, Wilmink JW, Geurts SME, de Vos-Geelen J; Dutch Pancreatic Cancer Group. Adjuvant and first-line palliative chemotherapy regimens in patients diagnosed with periampullary cancer: a short report from a nationwide registry. Acta Oncol 2022;61:591-6. [PMID: 35382678 DOI: 10.1080/0284186X.2022.2053199] [Reference Citation Analysis]
11 Rizzo A, Dadduzio V, Lombardi L, Ricci AD, Gadaleta-Caldarola G. Ampullary Carcinoma: An Overview of a Rare Entity and Discussion of Current and Future Therapeutic Challenges. Curr Oncol 2021;28:3393-402. [PMID: 34590592 DOI: 10.3390/curroncol28050293] [Reference Citation Analysis]
12 Luchini C, Scarpa A. Microsatellite instability in pancreatic and ampullary carcinomas: histology, molecular pathology and clinical implications. Hum Pathol 2022:S0046-8177(22)00154-X. [PMID: 35714836 DOI: 10.1016/j.humpath.2022.06.009] [Reference Citation Analysis]
13 Peng X, Jiao X, Zhao P, Zhu R, Sun Y, Zhou L. Influence of non-jaundice stage at diagnosis on clinicopathological features and long-term survival of patients with periampullary carcinomas. Medicine (Baltimore) 2019;98:e17673. [PMID: 31702620 DOI: 10.1097/MD.0000000000017673] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Wen G, Gu J, Zhou W, Wang L, Tian Y, Dong Y, Fu L, Wu H. Benefits of 18F-FDG PET/CT for the preoperative characterisation or staging of disease in the ampullary and duodenal papillary. Eur Radiol 2020;30:5089-98. [PMID: 32346795 DOI: 10.1007/s00330-020-06864-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Goktas Aydin S, Cakan Demirel B, Bilici A, Topcu A, Aykan MB, Kahraman S, Akbıyık I, Atci MM, Olmez OF, Yaren A, Geredeli C, Seker M, Urun Y, Karadurmus N, Aydin A. Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer. Curr Med Res Opin 2022;:1-24. [PMID: 35916475 DOI: 10.1080/03007995.2022.2108619] [Reference Citation Analysis]
16 Regalla DKR, Jacob R, Manne A, Paluri RK. Therapeutic options for ampullary carcinomas. A review. Oncol Rev. 2019;13:440. [PMID: 31565197 DOI: 10.4081/oncol.2019.440] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]